Skip to content

Pfizer PFE Derivative Liability

Derivative Liability at other companies

Merck & Co. logo
Merck & Co.MRK
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+5.0%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$143.68B+11.1%
Enterprise value$206.35B+9.2%
P/E11.9×
P/S2.3×+0.2×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%

Returns & leverage

See full
Return on equity10.6%
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilities.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's derivative liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's derivative liability?
Pfizer (PFE) reported derivative liability of $1.37B in Q1 2026.
How has Pfizer's derivative liability changed year-over-year?
Pfizer's derivative liability increased by 3.9% year-over-year, from $1.31B to $1.37B.
What is the long-term trend for Pfizer's derivative liability?
Over 5 years (2020 to 2025), Pfizer's derivative liability has grown at a 5.8% compound annual growth rate (CAGR), from $1.1B to $1.46B.